Q4 2023 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2024-02-14 · accession 0001104659-24-023144
$177.7M
Reported value
39
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 75525N107 | — | RAYZEBIO INC | $23.5M | 13.2% | 378,069 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $11.6M | 6.54% | 492,155 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $11.0M | 6.17% | 366,015 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $10.1M | 5.68% | 701,349 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $9.8M | 5.53% | 425,128 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $7.4M | 4.15% | 117,373 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $6.8M | 3.83% | 70,600 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $6.7M | 3.76% | 299,636 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $6.7M | 3.76% | 115,500 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $6.4M | 3.58% | 3,589,333 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $6.1M | 3.45% | 281,500 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC. | $6.1M | 3.42% | 231,882 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $5.8M | 3.29% | 1,310,000 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $5.5M | 3.09% | 2,368,000 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $5.2M | 2.93% | 324,600 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $5.0M | 2.83% | 119,489 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $4.6M | 2.58% | 160,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $4.6M | 2.56% | 76,100 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $4.3M | 2.41% | 77,000 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCES INC | $3.7M | 2.10% | 1,849,402 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $3.6M | 2.03% | 555,260 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $3.1M | 1.75% | 87,500 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC | $2.8M | 1.55% | 69,400 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $2.7M | 1.52% | 132,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $2.0M | 1.11% | 147,836 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $1.9M | 1.06% | 232,249 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $1.8M | 0.99% | 525,100 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $1.7M | 0.97% | 123,876 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS INC | $1.5M | 0.85% | 74,500 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $1.5M | 0.83% | 354,166 | Common | SOLE |
| 15117F807 | CLRBUSD | CELLECTAR BIOSCIENCES INC | $1.3M | 0.74% | 477,500 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $914,205 | 0.51% | 29,500 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE - ADR | $913,032 | 0.51% | 2,400 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $377,720 | 0.21% | 19,000 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $365,000 | 0.21% | 10,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $303,578 | 0.17% | 38,138 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $122,808 | 0.07% | 8,867 | Common | SOLE |
| 032797300 | AVXL | ANAVEX LIFE SCIENCES CORP | $22,500 | 0.01% | 1,000 | PUT | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO | $5,450 | 0.00% | 90,832 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.